Sarcopenia in the setting of nonalcoholic fatty liver

dc.article.number2
dc.catalogadorpau
dc.contributor.authorArrese, Marco
dc.contributor.authorCabello Verrugio, Claudio
dc.contributor.authorArab, Juan Pablo
dc.contributor.authorBarrera, Francisco
dc.contributor.authorBaudrand, René
dc.contributor.authorGuarda, Francisco J.
dc.contributor.authorGul, Iram
dc.contributor.authorCabrera, Daniel
dc.date.accessioned2025-03-20T19:40:41Z
dc.date.available2025-03-20T19:40:41Z
dc.date.issued2022
dc.description.abstractNonalcoholic fatty liver is a worldwide common problem with more prevalence in non-Asian populations that is closely correlated with the muscle-related disorder sarcopenia. The incidence of both health issues has been observed to be strongly interlinked where presence of one exacerbates the other. Nonalcoholic fatty liver disease (NAFLD) pathophysiology increases the muscle loss, while the onset of NAFLD in sarcopenic patients aggravates the liver problems as compared to non-sarcopenic patients. Scarcity of research on the subject provides very little evidence about the cause and effect of disorders. No FDA approved drugs are available to date for NAFLD and sarcopenia. Research is underway to understand the complex biochemical pathways involved in the development of both disorders. This review is a small contribution toward understanding sarcopenia in the setting of NAFLD that provides insight on the common pathophysiological profile of sarcopenia and NAFLD and portrays a novel way of delving into the subject by introducing the concept of cortisol crosstalk with the muscle-liver axis. Sarcopenia and NAFLD are considered metabolism-related problems, and cortisol, being a glucocorticoid, plays an important role in metabolism of fats, carbohydrates, and proteins. Cushing’s syndrome, characterized by abnormally elevated concentrations of blood cortisol/enhanced intracellular activity, shares many pathologic conditions (such as insulin resistance, metabolic syndrome, abnormal levels of specific cytokines, and obesity) with NAFLD and sarcopenia. Hence, cortisol can be a potential biomarker in sarcopenia and NAFLD. As cortisol activity at cellular level is controlled by 11β-hydroxysteroid dehydrogenase type 1 and 2 (11β-HSD1/2) enzymes that convert inactive steroid precursor into active cortisol, these enzymes can be targeted for the study of sarcopenia and NAFLD. Combined studies on NAFLD and sarcopenia with respect to cortisol open a new avenue of research in the understanding of both disorders. © The Author(s) 2022.
dc.fechaingreso.objetodigital2025-03-20
dc.fuente.origenORCID
dc.identifier.doi10.20517/mtod.2021.16
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-85141791568&partnerID=MN8TOARS
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/102899
dc.information.autorucEscuela de Medicina; Arrese, Marco; 0000-0002-0499-4191; 76095
dc.information.autorucEscuela de Medicina; Arab, Juan Pablo; 0000-0002-8561-396X; 132745
dc.information.autorucEscuela de Medicina; Barrera, Francisco; S/I; 1240448
dc.information.autorucEscuela de Medicina; Baudrand, René; 0000-0002-8655-4957; 1024
dc.information.autorucEscuela de Medicina; Guarda, Francisco J.; 0000-0001-9104-9499; 149942
dc.information.autorucEscuela de Medicina; Cabrera, Daniel; 0000-0002-5891-0459; 126029
dc.issue.numero1
dc.language.isoen
dc.nota.accesocontenido completo
dc.revistaMetabolism and Target Organ Damage
dc.rightsacceso abierto
dc.rights.licenseCC BY 4.0 Attribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleSarcopenia in the setting of nonalcoholic fatty liver
dc.typeartículo
dc.volumen2
sipa.codpersvinculados76095
sipa.codpersvinculados132745
sipa.codpersvinculados1240448
sipa.codpersvinculados1024
sipa.codpersvinculados149942
sipa.codpersvinculados126029
sipa.trazabilidadORCID;2025-03-03
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
sarcopenia in the setting of nonalcoholic fatty liver.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Description: